The Future of Interventional Psychiatry: Innovation, Economics and Strategic Growth

Interventional psychiatry is becoming an increasingly important part of the mental health ecosystem, expanding treatment options for treatment-resistant patients who have not achieved adequate relief through traditional medication management and psychotherapy modalities. Services such as transcranial magnetic stimulation (TMS), esketamine (SPRAVATO) and electroconvulsive therapy (ECT) provide clinicians with additional ways to address complex patient needs while creating compelling economic opportunities for the practice. Advances in neuromodulation and the development of psychedelic therapies could further reshape how psychiatric care is delivered.

Given the significant imbalance between supply and demand, growing awareness among patients and referring providers, and the natural fit with traditional psychiatry, interventional psychiatry has attracted considerable interest from private equity investors and strategic acquirers, fueling increased transaction activity and supporting strong valuations.

For independent interventional psychiatry practice owners, increased investor interest raises an important question: Is now the right time to explore a partnership? PGP believes the answer should depend on both the practice’s readiness and the resources needed to achieve its next stage of growth. Organizations with an established platform and a proven growth story may benefit from evaluating their options today, while others may create greater value by first strengthening operations, demonstrating new-location performance or building out complementary services. Exploring a partnership can help owners assess those alternatives, understand how potential partners would support their objectives, and determine when a transaction would best serve the practice, its clinicians and its patients.

This white paper authored by PGP’s senior leadership examines what we view as the forces shaping interventional psychiatry, the characteristics that influence buyer interest and valuation, and the considerations practice owners should weigh as they evaluate growth, investment and a potential transaction.

Heightened interest in the sector has been driven by outsized demand for services. An estimated 21 million U.S. adults experience a major depressive episode every year, according to the National Institute of Mental Health.¹ Of that population, 2.8 million adults have treatment-resistant depression, representing approximately 31% of adults with medication-treated major depressive disorder.² Interventional psychiatry addresses an important limitation of traditional mental health care and provides access and greater clinical efficacy to a patient population that has historically resisted traditional treatment modalities. Beyond strong demand, broader awareness and increased adoption of interventional psychiatry services have drawn greater attention to the sector as well. Spravato’s January 2025 FDA approval as a standalone treatment for adults with treatment-resistant depression further expanded prescribing flexibility.³ These milestones demonstrate growing clinical use, while suggesting meaningful room for expansion relative to the underlying patient population.

The ability to integrate interventional psychiatry offerings into traditional mental health practices further strengthens the investment thesis. PGP recently connected with Jordan Klear, Chairman and CEO of Sound Minds Behavioral, who highlighted the strategic benefits of the partnership and the expanding opportunities within interventional psychiatry. “Interventional psychiatry is an attractive space today in behavioral health as we are able to leverage our medication management patient base to provide additional services that were not previously available to them such as TMS, Spravato and in the near future, psychedelics.” Practices offering medication management and psychotherapy already care for patients who may become appropriate candidates for interventional treatment. Adding these capabilities can create a more comprehensive continuum of care, reduce the need for outside referrals and support growth through established patient relationships and referral networks.

In PGP’s view, integrating interventional psychiatry services creates an attractive opportunity for strategic acquirers to broaden existing services and for private equity investors to build organizations with multiple complementary services. For interventional psychiatry practice owners, growing demand, investor interest and transaction activity create three strategic imperatives: understand the economics of each treatment modality, build the infrastructure needed to support responsible growth, and preserve the flexibility to remain independent or pursue a partnership from a position of strength.

Interventional psychiatry encompasses distinct treatment modalities, each shaping how a practice delivers care and builds its clinical platform. Differences in treatment protocols, staffing, infrastructure and payor coverage influence both patient access and practice economics. The following sections examine the treatment modalities and their implications for providers and investors.

Transcranial Magnetic Stimulation (TMS)
TMS has become an established component of outpatient interventional psychiatry, particularly for patients with depression who have not responded adequately to antidepressant treatment. Delivered without anesthesia, it offers practices a procedural treatment that can operate within an office setting. Adoption is also expanding into younger populations: following NeuroStar’s FDA clearance for patients ages 15–21, Neuronetics reported coverage expansions from several major commercial insurers in 2025. Broader clinical eligibility represents an important growth driver for the modality, particularly as expanded payor coverage makes treatment accessible to more patients.

From an investment perspective, TMS offers the potential to grow treatment capacity without a proportional increase in psychiatrist appointment hours. Trained technicians can administer routine sessions under appropriate physician supervision, while clinicians oversee evaluation, treatment planning and ongoing care. In PGP’s view, strategic buyers can use a technician-supported model to introduce TMS across existing offices, serve appropriate patients already receiving medication management and develop referral relationships with outside providers. An acquisition can therefore bring both an established treatment business and the clinical and operational expertise needed to expand the service across a larger platform.

TMS practice economics, however, depend heavily on utilization. Equipment purchases or leases, service agreements, treatment-related fees, dedicated space and staffing create a cost base that must be supported by consistent patient starts and completed treatment courses. Once the TMS infrastructure is in place, additional volume can improve margins, but an underutilized TMS device can weigh on practice profitability. Buyers consequently will evaluate reimbursement by payor, authorization approval rates, referral-to-treatment conversion, patient attendance and collections. Conventional treatment schedules require frequent visits over several weeks, creating a practical barrier for patients balancing work, transportation and family responsibilities. Coverage requirements can add further friction through documentation of prior treatment failures and other medical necessity criteria.

Eskatime (Spravato)
Spravato has also become an increasingly important offering within interventional psychiatry, providing an FDA-approved nasal treatment for adults with treatment-resistant depression. Its January 2025 approval as a standalone treatment expanded prescribing flexibility by removing the requirement for concurrent oral antidepressant use in this population.³ Adoption continues to gain traction, with Johnson & Johnson reporting increased physician and patient demand as a driver of Spravato’s growth in 2025.^{6 7}

For strategic buyers and private equity investors, Spravato offers an opportunity to expand services within existing practices and build ongoing treatment relationships. Patients typically transition from a more frequent induction schedule to less frequent maintenance treatment, depending on clinical response.

The principal constraint is operational intensity. Spravato must be administered at a REMS-certified treatment center, with patients monitored for at least two hours after administration.⁸ The REMS and monitoring requirements make staffing, scheduling and available treatment chairs important determinants of capacity, while transportation needs and repeated visits can limit patient access. For acquirers, the strongest practices will demonstrate an ability to convert referrals into authorized treatment, maintain patient engagement and expand capacity while meeting clinical and safety requirements.

Emerging treatments and technologies could further reshape interventional psychiatry, from accelerated and personalized neuromodulation to psychedelic-assisted therapies. For providers and investors, emerging treatments and technologies offer potential avenues for growth and differentiation, although their commercial opportunity will depend on clinical evidence, regulatory pathways, reimbursement and the infrastructure required to deliver care.
Compass Pathways, one of the most developed psychedelic companies in the U.S., expects to complete its rolling FDA application for its COMP360 psilocybin product in Q4 2026. Pending FDA approval, a commercial launch is targeted for the first half of 2027.⁹ However, the Drug Enforcement Administration would also need to reclassify psilocybin for a commercial launch to happen.

•Demonstrated Clinical Outcomes: Use standardized assessments to demonstrate treatment effectiveness and support clinical credibility. Track baseline and follow-up depression scores, response and remission rates, treatment completion and patient-reported satisfaction. Define measures consistently and report outcomes by modality, including the percentage of patients with complete follow-up data.

•Utilization and Practice Economics: Demonstrate that treatment capacity translates into profitable care delivery. Track new patient starts, completed sessions, TMS device utilization, Spravato treatment-chair utilization, cancellations and no-shows, and staffing cost per session. Measure net collections and contribution margin by modality, separating drug acquisition costs from service economics.

•Patient Access and Referral Conversion: Build a reliable process for moving appropriate patients from inquiry through treatment. Track referral-to-consultation conversion, consultation-to-treatment conversion, authorization approval rates, days from referral to first treatment and reasons patients do not start. Monitor referral volume by source and clinically appropriate referrals from existing psychiatry patients.

•Compliance and Revenue Cycle: Maintain consistent clinical oversight, documentation, credentialing and modality-specific safety processes, including Spravato REMS requirements. Track denial rates, appeal success, days in accounts receivable, receivables over 90 days, net collection rates and documentation audit results. Buyers will also assess whether reimbursement supports sustainable margins by payor and modality.

•Repeatable Growth: Show that expansion can generate attractive returns through new locations, additional treatment capacity and complementary services. Track capital required per opening or service launch, time to first patient, months to operating breakeven, patient-start growth and performance against budget. Demonstrate that growth is supported by repeatable staffing, referral development and operating processes.

The buyer universe for interventional psychiatry spans three principal groups, each with a distinct investment rationale. Understanding the differences among the three buyer groups helps practice owners identify partners whose goals align with their clinical model and growth priorities. PGP has had significant experience vetting and evaluating interventional psychiatry buyers within each of the three categories.

•Private Equity Firms and Family Offices: Investors seeking an initial platform investment from which to build a larger business through acquisitions, new locations and service expansion. Private equity firms and family offices typically prioritize strong clinical leadership, established infrastructure and a repeatable growth model.

•Outpatient Mental Health Platforms: Organizations seeking to add specialty treatment capabilities to an existing base of psychiatry and therapy services. Outpatient mental health platforms may see opportunities to serve appropriate patients within their networks, retain more of the care continuum and introduce TMS or Spravato across existing offices.

•Pure-Play Interventional Psychiatry Buyers: Providers focused on TMS, Spravato, ketamine and related treatments that use acquisitions to expand geographic reach, build local density and broaden capabilities. Their existing clinical and operating infrastructure can support integration and help acquired practices increase treatment capacity.

Through its broader focus on healthcare services, PGP maintains longstanding relationships with private equity firms, family offices and strategic acquirers investing in provider businesses. The table below highlights select transactions involving interventional psychiatry providers, including practices offering TMS, Spravato and ketamine alongside traditional mental health services. PGP’s experience advising mental health providers offers insight into how buyers evaluate these businesses, the characteristics that drive interest and the partnership structures available to practice owners.
PGP’s relationships help practice owners explore options across both established interventional psychiatry buyers and outpatient mental health platforms seeking to add specialty treatment capabilities, with an emphasis on finding the right fit for long-term success.

PGP has advised on a number of psychiatry transactions over the years, making it one of the most active transaction advisors in the industry. Select highlighted transactions include:

PGP advised The Ross Center (“TRC”) in its Partnership with ARC Health (Thurston Group). TRC is the leader in psychiatric and psychological care in Washington, Northern Virginia, and New York, with more than 50 board-certified clinicians. The transaction represents ARC’s expansion into the Washington, DC-area and greater Mid-Atlantic markets.

PGP advised Silver Lake Psychology in its multi-state Partnership with ARC Health (Thurston Group). Silver Lake’s more than 400 providers offer a range of counseling services from offices in California, Colorado, Tennessee, and Washington, DC.

PGP believes interventional psychiatry is well positioned for continued investment as substantial unmet patient demand, broader treatment adoption and the integration of advanced therapies into traditional mental health practices create opportunities for growth. Investor interest and transaction activity reflect the appeal of businesses that can expand access to care while demonstrating strong clinical outcomes and sustainable practice economics.
As the sector matures and transactions become more commonplace, interventional psychiatry practice owners will face a broader range of potential partners and transaction structures. Each brings different expectations around clinical autonomy, service expansion, physician compensation, ongoing ownership and the pace of growth. Evaluating these differences requires a clear understanding of the organization’s priorities and what its owners hope to achieve—whether that means accelerating expansion, gaining operational support, pursuing liquidity or establishing a succession plan.
PGP’s role is to help interventional psychiatry practice owners navigate the choices involved in a sale or partnership, aligning transaction timing, economics and partnership terms with the long-term objectives of the organization and its clinicians. In PGP’s view, a successful transaction begins with preparation and a thoughtful assessment of the available options. Understanding how buyers will evaluate the practice, addressing operational gaps and assessing a prospective partner’s track record can strengthen both negotiating leverage and confidence in the ultimate decision.